<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02123446</url>
  </required_header>
  <id_info>
    <org_study_id>15313</org_study_id>
    <secondary_id>A3Q-ME-AFBP</secondary_id>
    <nct_id>NCT02123446</nct_id>
  </id_info>
  <brief_title>A Study of Cephalexin Capsules in Healthy Participants</brief_title>
  <official_title>A Randomized, Open-label, Two-period, Two-treatment, Two-sequence, Crossover Study to Evaluate the Bioequivalence of Single Doses of Two Oral Preparations in Capsules With 250 mg of Cephalexin (Keflex® Made in Mexico by Eli Lilly y Compañía de México, S.A. de C.V. vs. Keflex® Made in Italy by Facta Farmaceutici S.p.A. for Eli Lilly y Compañía de México, S.A. de C.V.) in Fasting Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare two different preparations of an antibiotic called
      cephalexin in capsules to determine if they are essentially the same. The study has two
      periods. Participants will receive one preparation of cephalexin in each period. At least 7
      hours will pass between the study periods. The study is expected to last about 2 days for
      each participant, not including screening or follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Versus Time Curve of Cephalexin From Time Zero to Infinity [AUC(0-∞)] of Cephalexin Following a Single Dose</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, and 7.0 hours in each period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of Cephalexin</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, and 7.0 hours in each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Time to Reach Maximum Observed Concentration (Tmax) of Cephalexin Following a Single Dose Maximum</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, and 7.0 hours in each period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cephalexin (Reference)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cephalexin (Test)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cephalexin manufactured in Italy by Facta administered once orally in one of two study periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cephalexin</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Cephalexin (Reference)</arm_group_label>
    <arm_group_label>Cephalexin (Test)</arm_group_label>
    <other_name>Keflex®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participation will be voluntary.

          -  The body mass index of participants should be between 18-27.

          -  Participants should have a good health status.

          -  Limits of variation allowed within normal values at screening will be: blood pressure
             (seated) up to 139 millimeters of mercury (mm Hg), for systolic, and up to 89 mm Hg
             for diastolic; heart rate between 60 and 100 beats per minute, and respiratory rate
             between 14 and 20 breaths per minute.

          -  Hepatitis B and C and human immunodeficiency virus (HIV) negative.

          -  Drug abuse or alcohol detection test approximately 12 hours before administering the
             study medication.

          -  Serum pregnancy test (beta human chorionic gonadotropin) at screening and urine
             pregnancy test approximately 12 hours before administering the study medication.

        Exclusion Criteria:

          -  Participants with any clinically significant abnormality in their vital sign constants
             recorded at screening.

          -  Sponsor´s and/or site employees.

          -  Abnormal 12 lead electrocardiogram (ECG) that in the opinion of the investigator
             places the participant at an unacceptable risk for study participation, Bazett
             corrected QR interval (QTcB) &gt; 470 millisecond (msec) for women and &gt; 450 msec for
             men.

          -  Participants with history of cardiovascular, renal, hepatic, muscular, metabolic,
             gastrointestinal diseases, including constipation, neurological, endocrine,
             hematopoietic diseases, or any type of anemia, asthma, mental disease, or other
             organic abnormalities.

          -  Participants with a creatinine clearance &lt; 80 milliliter per minute (mL/min) based on
             the Cockcroft-Gault equation.

          -  Participants requiring any medication during the study, apart from the medication
             which is being studied.

          -  Participants with history of dyspepsia, gastritis, esophagitis, duodenal or gastric
             ulcer.

          -  Participants who have been exposed to medications known as hepatic enzyme inducers or
             inhibitors or who have been taking potentially toxic medications within the 30 days
             prior.

          -  Participants who have received any medication, including vitamins (with or without
             medical prescription) or herbal-based remedies 30 days (or 7 half-lives) prior to the
             beginning of the study.

          -  Participants who have been hospitalized for any condition within six months to the
             beginning of the study.

          -  Participants who have received investigational drugs within the 60 days prior to the
             study.

          -  Participants allergic to any medication, food, or substance.

          -  Participants who require therapy with nephrotoxic drugs.

          -  Participants who have donated 450 mL of blood or more within the 60 days prior to the
             beginning of the study.

          -  Participants with history of drug and alcohol abuse.

          -  Participants with special diet requirement for any cause.

          -  Participants with positive to pregnancy test or are breastfeeding.

          -  Participants on hormonal treatment by any route.

          -  Participants who have not been recorded in the page of the Comisión Federal para la
             Protección contra Riesgos Sanitarios (COFEPRIS).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mexico City</city>
        <zip>14610</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2014</study_first_submitted>
  <study_first_submitted_qc>April 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2014</study_first_posted>
  <results_first_submitted>May 8, 2015</results_first_submitted>
  <results_first_submitted_qc>May 8, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 27, 2015</results_first_posted>
  <last_update_submitted>June 19, 2015</last_update_submitted>
  <last_update_submitted_qc>June 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cephalexin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cephalexin Dosing Sequence AB</title>
          <description>Each participant was administered Cephalexin A formulation (Treatment A, Reference – 1 occasion) and Cephalexin B formulation (Treatment B, Test – 1 occasion).There was an interval of 1 day between doses.</description>
        </group>
        <group group_id="P2">
          <title>Cephalexin Dosing Sequence BA</title>
          <description>Each participant was administered Cephalexin B formulation (Treatment B, Test – 1 occasion) and Cephalexin A formulation (Treatment A, Reference – 1 occasion).There was an interval of 1 day between doses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>Each participant was administered Cephalexin A formulation (Treatment A, Reference – 1 occasion) and Cephalexin B formulation (Treatment B, Test – 1 occasion).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.4" spread="8.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Area Under the Concentration Versus Time Curve of Cephalexin From Time Zero to Infinity [AUC(0-∞)] of Cephalexin Following a Single Dose</title>
        <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, and 7.0 hours in each period</time_frame>
        <population>All participants who had at least one study treatment and had evaluable pharmacokinetic (PK) data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cephalexin (Reference)</title>
            <description>Cephalexin(Treatment A) manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.</description>
          </group>
          <group group_id="O2">
            <title>Cephalexin (Test)</title>
            <description>Cephalexin(Treatment B) manufactured in Italy by Facta administered once orally in one of two study periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Concentration Versus Time Curve of Cephalexin From Time Zero to Infinity [AUC(0-∞)] of Cephalexin Following a Single Dose</title>
          <population>All participants who had at least one study treatment and had evaluable pharmacokinetic (PK) data.</population>
          <units>Hour*microgram per milliliter(h*µg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.102" spread="16.751"/>
                    <measurement group_id="O2" value="19.207" spread="17.551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Maximum Concentration (Cmax) of Cephalexin</title>
        <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, and 7.0 hours in each period</time_frame>
        <population>All participants who had at least one study treatment and had evaluable pharmacokinetic (PK) data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cephalexin (Reference)</title>
            <description>Cephalexin(Treatment A) manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.</description>
          </group>
          <group group_id="O2">
            <title>Cephalexin (Test)</title>
            <description>Cephalexin(Treatment B) manufactured in Italy by Facta administered once orally in one of two study periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Maximum Concentration (Cmax) of Cephalexin</title>
          <population>All participants who had at least one study treatment and had evaluable pharmacokinetic (PK) data.</population>
          <units>Microgram per milliliter(µg/ml)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.976" spread="24.981"/>
                    <measurement group_id="O2" value="9.710" spread="39.223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Time to Reach Maximum Observed Concentration (Tmax) of Cephalexin Following a Single Dose Maximum</title>
        <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, and 7.0 hours in each period</time_frame>
        <population>All participants who had at least one study treatment and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cephalexin (Reference)</title>
            <description>Cephalexin(Treatment A) manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.</description>
          </group>
          <group group_id="O2">
            <title>Cephalexin (Test)</title>
            <description>Cephalexin(Treatment B) manufactured in Italy by Facta administered once orally in one of two study periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Time to Reach Maximum Observed Concentration (Tmax) of Cephalexin Following a Single Dose Maximum</title>
          <population>All participants who had at least one study treatment and had evaluable PK data.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" spread="0.765"/>
                    <measurement group_id="O2" value="1.000" spread="0.876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cephalexin (Reference)</title>
          <description>Cephalexin(Treatment A) manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.</description>
        </group>
        <group group_id="E2">
          <title>Cephalexin (Test)</title>
          <description>Cephalexin(Treatment B) manufactured in Italy by Facta administered once orally in one of two study periods.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

